Gasherbrum Bio, Inc., A Wholly Owned Subsidiary Of Structure Therapeutics
Clinical trials sponsored by Gasherbrum Bio, Inc., A Wholly Owned Subsidiary Of Structure Therapeutics, explained in plain language.
-
New obesity pill shows promise in body fat reduction trial
Disease control OngoingThis study tests a new drug called aleniglipron (GSBR-1290) in 71 adults with obesity (BMI 30 or higher). Participants take the drug or a placebo daily for 40 weeks. The main goal is to see how much total body fat changes, measured by a special X-ray scan.
Phase: PHASE2 • Sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
New pill shows promise for diabetes and weight loss in early trial
Disease control OngoingThis study tests a new medication called aleniglipron in adults with type 2 diabetes who are also overweight or obese. The main goal is to see if the drug is safe and tolerable at different doses. Researchers will also check if it helps with weight loss and blood sugar control. A…
Phase: PHASE2 • Sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics • Aim: Disease control
Last updated May 11, 2026 20:50 UTC
-
New daily pill shows promise for weight loss in major trial
Disease control OngoingThis study tests an experimental daily pill, aleniglipron, to help people with obesity or overweight lose weight. About 220 adults will receive either the drug or a placebo for 36 weeks, followed by an optional 36-week extension where everyone gets the drug. The goal is to see ho…
Phase: PHASE2 • Sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics • Aim: Disease control
Last updated May 05, 2026 11:53 UTC